  Use of next-generation sequencing technologies to transcriptomics (RNA-seq)
for gene expression profiling has found widespread application in studying
different biological conditions including cancers. However, RNA-seq experiments
are still small sample size experiments due to the cost. Recently, an increased
focus has been on meta-analysis methods for integrated differential expression
analysis for exploration of potential biomarkers. In this study, we propose a
p-value combination method for meta-analysis of multiple related RNA-seq
studies that accounts for sample size of a study and direction of expression of
genes in individual studies. The proposed method generalizes the inverse-normal
method without increase in computational complexity and does not pre- or
post-hoc filter genes that have conflicting direction of expression in
different studies. Thus, the proposed method, as compared to the
inverse-normal, has better potential for the discovery of differentially
expressed genes (DEGs) with potentially conflicting differential signals from
multiple studies related to disease. We demonstrated the use of the proposed
method in detection of biologically relevant DEGs in glioblastoma (GBM), the
most aggressive brain cancer. Our approach notably enabled the identification
of over-expression in GBM compared to healthy controls of the oncogene RAD51,
which has recently been shown to be a target for inhibition to enhance
radiosensitivity of GBM cells during treatment. Pathway analysis identified
multiple aberrant GBM related pathways as well as novel regulators such as
TCF7L2 and MAPT as important upstream regulators in GBM. The proposed method
provides a way to establish differential expression status for genes with
conflicting direction of expression in individual RNA-seq studies. Hence,
leading to further exploration of them as potential biomarkers for the disease.
